syqe-inhaler

The World's First Selective-Dose Pharmaceutical Grade Medicinal Plants Inhaler

jurnal2
We finally may have a delivery system for medical cannabis that is effective, stable, safe and easy to use. Journal of Pain & Palliative Care Pharmacotherapy - Reviewer
Close

The Syqe Inhaler™

A first-in-class pocket-sized selective-dose cannabis inhaler, poised to become the most advanced and versatile inhalation-based drug delivery platform of its kind. The Syqe Inhaler utilizes selective 100 microgram dosing precision, realtime thermal & flow controllers, lung interfacing and wireless connectivity.
This new level of precision will allow patients to reach the coveted optimum balance between symptom relief and psychoactivity, regaining their quality of life. The platform is further comprised of proprietary raw drug Structural-Modification methods, uniquely identified preloaded cartridges and a linked clinical database serving physicians, researchers and healthcare entities.

Proprietary

Raw Plant

01-weed-X2

Standardized Production
Pharmaceutical Grade

Structural Modification

02-Dose-X2-2

No Chemical Alteration
No Added Excipients

Preloaded Cartridges

2711-cartrige

Uniquely Identified
Childproof

Metered-Dose Delivery

inhaler-syqe

100 Microgram Resolution
Selective Dosing

Syqe Inhaler Exo® (For Hospital Use)

2711-exo

A hospital version selective-dose cannabis inhaler for professional healthcare use, featuring a caregiver interface. Aimed at providing nurses and caregivers with a certified medical device for use in pain clinics, cancer centers, intensive care units and other medical institutions. The Syqe Inhaler Exo is available for hospital use in Israel.

Clinical

Clinical trials are at the forefront of our strategy, providing clinical evidence and leveraging the full potential of our technology. Our recent trial demonstrated the feasibility and the first-in-class positioning of our inhaler platform. The objective of the study was to assess the potential of the Syqe Inhaler Exo in terms of pharmacokinetics, accuracy of dosing, safety, tolerability, efficacy and ease of use. This trial suggests the potential use of the Syqe Inhaler Platform, producing a Δ⁹-THC pharmacokinetic profile with low-interindividual variation of Cmax, achieving pharmaceutical standards for inhaled drugs.

The Pharmacokinetics, Efficacy, Safety, and Ease of Use of a Novel Portable Metered-Dose Cannabis Inhaler in Patients With Chronic Neuropathic Pain: A Phase 1a Study Elon Eisenberg, Miri Ogintz, and Shlomo Almog
Journal of Pain & Palliative Care Pharmacotherapy
September 2014, Vol. 28, No. 3


Dosing Precision (Interindividual Variability)

Zoom
precision-graph

Interindividual variability of Δ⁹-THC plasma Cmax obtained by various modes of delivery.

Dosing Precision (Inter - individual variability)

graph-2

Source: Eisenberg et al. The PK, efficacy, safety and ease of use of a novel portable metered-dose cannabis inhaler in a cohort of patients with chronic neuropathic pain - 2014.

* Average inter-individual CV of referenced clinical studies.
† Kavita Gumbhir-Shah et al. PK and PD of Cumaltive Single Doses of Inhaled Salbutamol 1999
† Paula J. Anderson et al. PK of (R,S)-Albuterol after Aerosol Inhalation in Healthy Adult Volunteers 1998

Efficiency (ng/ml per mg)

Zoom
efficiency-graph

Δ⁹-THC plasma Cmax levels per mg administered by various modes of delivery.

Efficiency ng/ml per mg delta9-THC

graph-3

Source: Eisenberg et al. The PK, efficacy, safety and ease of use of a novel portable metered-dose cannabis inhaler in a cohort of patients with chronic neuropathic pain - 2014.

* Average Plasma Cmax of referenced clinical studies.

Pharmacokinetic Data (Syqe Inhaler Exo)

Zoom
raw-pharma-graph

Δ⁹-THC plasma levels following single-dose inhalation of 15.1 ± 0.1 mg cannabis flos

Pharmacokinetic Data (Syqe Inhaler Exo)

graph-1
Cmax (ng/ml) Tmax (min) AUC (ng∙min/ml)
Mean 38 3 607
SD 10 1 200

In the study, 15.1mg ± 0.1 of Cannabis 19.9% THC (Bedrocan) was administered using the Syqe Inhaler Exo in a single inhalation to 10 chronic pain patients (2 excluded). In addition, there was robust pain relief (VAS scale) following a single inhalation lasting up to 90 minutes.

Clinical Goal

Zoom
graph-3

Accurately enter the therapeutic window and seamlessly maintain it.

Clinical Goal

graph-4

Accurately enter the therapeutic window between Psychoactivity and Symptom relief, while seamlessly maintaining it.

About Us

Syqe Medical aspires to transform cannabis and other botanicals into mainstream medical drugs. Our vision is to decentralize drug development and streamline its clinical testing in a 21st century fashion.

To achieve these goals our company has been implementing cutting-edge technologies for over 5 years and employs a multi-disciplinary team of electronic engineers, mechanical engineers, industrial designers, chemists, biologists, physicians and Pharmacologists.    

Management

Eytan Hyam M.D. Chairman of the Board

Eytan Hyam is Syqe’s Chairman of the Board. Eytan is a former Director-General of Israel’s Ministry of Health, and the Soroka and Assuta Medical Centers. An ex-director of Clalit HMO central district, Eytan is a qualified general practitioner, and graduate of Israel’s Ben Gurion Medical School, Beer Sheva.

Perry Davidson Founder, CEO

Perry Davidson is the Founder and CEO of Syqe Medical. An inventor of patents in various fields, including the company’s core technology, Perry was Co-founder and former CEO of Israel’s largest medical cannabis production company. He has more than a decade’s experience in controlled substance regulation and state implementation.

James Amihood General Manager

James Amihood is Syqe’s General Manager. A South African by birth, James has 25 years of management experience, holding senior positions at global, Nasdaq-traded healthcare companies, managing subsidiaries and heading Business Development. James holds an MBA, B.Sc. in Chemistry, and a B.Sc. in industrial engineering.

Revital Rodovsky Chief Financial Officer

Revital Rodovsky is Syqe’s CFO. With almost 15 years’ executive experience, Revital served as CFO for a number of tech companies in the medical device and communication spaces, successfully leading a string of mergers and acquisitions. Revital holds a certified public accountant diploma and a BA in Business Management.

Daniella Atzmony PhD Chief IP Officer & General Counsel

Daniella Atzmony is Syqe’s chief intellectual property officer and general counsel, responsible for legal and IP issues. An advocate and patent attorney, Daniella previously worked at one of Israel’s largest patent firms, and has provided in-house IP advice to a number of start-ups. Daniella holds a PhD in Biology, and chairs Israel’s In-House IP Managers Forum.

Lea Lak M.D. Medical Director

Lea Lak is Syqe’s Medical Director, responsible for clinical trials and regulatory matters. Lea has led teams in multiple medical device companies, heading research and clinical trials in challenging, multi-disciplinary projects: as Medical Director of CorAssist, Medical Manager of Polyheal and Medical Specialist at ByPass. Lea is a graduate of Hadassah Medical School, Jerusalem.  

Benjamin Schwartz B.Eng VP R&D

Benjamin Schwartz leads Syqe’s multidisciplinary R&D team. An electronics engineer by trade, he’s led a number of projects for defence companies, such as Rafael and Elbit, focusing on aviation and special forces’ technologies. Benny was one of Syqe’s first employees.

Seth Kindler M.D. Chief Science Officer

Seth Kindler is Syqe’s Chief Science Officer. A psychiatrist with more than 20 years’ experience in the biopharmaceutical sector, Seth served as Medical Director at Pharmos, and consulted for several cannabis-based startups. Seth is a former Deputy Director of the Sheba Hospital’s Psychiatric Ward, and headed the Israeli Army’s PTSD Clinical Research Program.    

Prof. Elon Eisenberg M.D. Scientific Advisory Board – Pain Management

Elon Eisenberg heads up Syqe’s Scientific Advisory Board for Pain Management, and sits on the Executive Board of the European Pain Federation. Elon leads the Pain Research Unit at Rambam Medical Center. He’s also an associate professor of Neurology & Pain at the Technion.

Brian Cooper Board Member

Brian Cooper is a member of Syqe’s Executive Board, and co-founder investor. Brian is the founder and former CFO of retail software company, Retalix, which was sold to NCR for $650m. He’s an active Angel and early-stage investor in a number of IT and Life Science companies.

Contact Us

Company Headquarters

Tel Aviv 6816914, Israel
Tel: +972-(0)3-560-1097
Fax: +972-(0)3-761-7886
info@syqemed.com

Careers

We're looking for great people to join our team. For the latest openings, click here

Media Enquiries

media@syqemed.com

Area of interest